Expression of intermedin in lung cancer patients and its clinical significance

( views:79, downloads:0 )
LIU Hao(Department of Oncology, Clinical College of Anhui Medical University and Beijing Military Region, Beijing 100700, China)
YU Zhong-he()
Journal Title:
Volume 23, Issue 05, 2011
Key Word:
Lung neoplasms;Angiogenesis modulating agents;Anoxia

Abstract: Objective To investigate the expression of intermedin (IMD) in plasma and tissues of lung cancer patients compared with control group and to explore the relationship of IMD with the stage and pathological type of lung cancer. Methods The content of IMD in plasma of 88 lung cancer patients measured using ELISA, 36 lung cancer tissue using immunohistochemistry, compared with control groups. Results Healthy control group IMD level [(38.68±12.65) pg/ml] was lower than lung cancer group [(81.61 ± 30.78) pg/ml] (t =-5.818, P <0.05); There was no significant difference of IMD between small cell [(68.61 ± 30.01) pg/ml] and non-small cell lung cancer [(75.51 ±32.74) pg/ml] (t =-0.680, P >0.05); IMD in stage Ⅳ is higher than stage Ⅰ - Ⅲ (t =-3.444, -3.093, -3.955, P <0.05); IMD with distant metastasis is significantly higher than that without distant metastasis (t =8.052, P =0.000). IMD expression in lung cancer tissues [23/36 (63.9 %)] is significantly higher than adjacent tumor tissues [5/21 (23.8 %)] (x2= 8.525, P <0.05). IMD in Stage Ⅲ[14/17(82.4 %)] is significantly higher than in stage Ⅰ [1/5 (20.0 %)] (x2 = 6.924, P =0.009). Conclusion The expression of IMD in lung cancer patients is significantly higher than control groups. Expression has correlation with stage and metastasis, which might play a vital role in the pathogenesis of lung cancer.

  • [1]Roh J,Chang CL,Bhalla A,et al.Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes.J Biol Chem,2004,279:7264-7274.
  • [2]Takei Y,Hyodo S,Katafuchi T,et al.Novel fish derived adrenomedullin in mammals:structure and possible function.Peptides,2004,25:1643-1656.
  • [3]Bell D,McDermott BJ.Intermedin (adrenomedullin-2):a novel counter-regulatory peptide in the cardiovascular and renal systems.Br J Pharmacol,2008,153:247-262.
  • [4]Robert S,Smith J,Lin G,et al.Intermedin is a new angiogenic growth factor.Am J Physiol Heart Circ Physiol,2009,297:H1040-1047.
  • [5]杨继元,熊杏安,杜伟.非小细胞肺癌组织中VEGF-C及其受体VEGFR-3的表达与淋巴结转移的关系.肿瘤研究与临床,2010,22:52-54.
  • [6]Lee TH,Seng S,Sekine M,et al.Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.PLoS Med,2007,4:e186-e186.
  • [7]Albertin G,Sorato E,Oselladore B,et al.Involvement of vascular endothelial growth factor signaling in CLR/RAMP1 and CLR/RAMP2-mediated pro-angiogenic effect of intennedin on human vascular endothelial cells.Int J Mol Med,2010,26:289-294.
  • [8]Thurston G,Noguera I,George D.The delta paradox:DLL4 blockade leads to more tumour vessels but less tumour growth.Nat Rev Cancer,2008,7:327-231.
  • [9]Pfeil U,Aslam M,Paddenberg R,et al.Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary mierovascular permeability.Am J Physiol Lung Cell Mol Physiol,2009,297:L837-L845.
  • [10]Morimoto R,Satoh F,Murakami O,et al.Expression of adrenomedullin 2/intermedin in human adrenal rumors and attached non-neoplastic adrenal tissues.J Endocrinol,2008,198:175-183.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615